Dystrogen TherapeuticsS.A.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2018-02-19
Share capital
179 220,00 PLN
Activity description

Dystrogen Therapeutics is a clinical-stage biotechnology company developing chimeric cell therapy for muscle wasting disorders, especially Duchenne muscular dystrophy (DMD). It is testing DEC cell therapy, designed to work across DMD genetic mutations without immunosuppression. The company reports outcomes such as increased muscle force, reduced fatigue, and larger muscle fiber diameter and volume.

Registered address
ul. Kasztelańska 49, 60-316 Poznań, Poland
Website
dystrogen.comWebsite active
Social media

Industry

Bank accounts

Was a VAT taxpayer from 2018-03-30 to 2024-06-14. Removed from VAT register

Reason for removal: Art. 96 ust. 9 pkt 2 (contact with the taxpayer or their representative is impossible despite documented attempts)

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

MSiG notices

Publication dateEvent
Feb 18, 2025Dissolution without liquidation opened
Nov 18, 2022Dissolution without liquidation opened
Sep 3, 2019Commercial Companies Code notice

Public aid

PurposeGross amount
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
$4,622
Aid for SME access to finance — aid for start-ups
$381.2K

Tenders

No recorded participation in tenders.

Authorized Representatives

Manner of representation

Each member of the management board acting independently is authorized to make declarations of will on behalf of the company and to represent the company.

Supervisory board

Selvon St Clair — Supervisory Board Member

Beneficial owners

Person
Krzysztof Siemionow (49)
Maria Siemionow (76)

Competitors

Name
Polpharma BiologicsS.A.
BiotechnaS.A.
FamicordtxS.A.
MolecureS.A.

Change history

DateEvent
2019-10-22Share capital change
2018-02-19Entered in the register

FAQ

Last updated: 2026-03-29